NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
Clinical Trials
21 trialsNCT02691780 2019-12-30
Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
Samsung Medical Center
Phase NA Withdrawn
NCT02747537 2019-09-09
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
Phase 2 Withdrawn
NCT00810394 2018-01-10
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
University of California, Davis
Phase 2 Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00572078 2017-09-25
Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
Indiana University
Phase 1 Completed
NCT02450149 2017-03-13
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
NCT01450384 2016-02-23
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
Virginia Commonwealth University
Phase 1 Completed
NCT01128998 2015-10-19
Sorafenib Plus S-1 in Advanced Solid Tumors
National Health Research Institutes, Taiwan
Phase 1 Completed
NCT00126620 2015-07-23
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
University Health Network, Toronto
Phase 1 Completed
NCT00255658 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00984425 2014-12-02
The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Istituto Clinico Humanitas
Phase 1 Completed
NCT00759928 2014-07-02
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00121264 2014-06-17
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00436579 2014-02-24
Sorafenib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00107432 2013-06-05
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
National Cancer Institute (NCI)
Phase 2 Completed
NCT00495872 2012-10-18
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00573690 2012-04-24
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00509613 2009-09-18
Phase 1 Study With Sorafenib and Sirolimus
Radboud University Medical Center
Phase 1 Completed
NCT00794859 2009-08-04
SMS
King's College London
Phase 2 Unknown